Thu, 28/11/2013 - 13:08
By News team
Peginterferon alfa with ribavirin is the only licensed treatment for young people with chronic hepatitis C
Treatment for children and young people with chronic hepatitis C should include the option of peginterferon alfa in combination with ribavirin, recommends the National Institute for Health and Care Excellence in its 300th technology appraisal, issued today (27 November).
"Treatment with peginterferon alfa and ribavirin can decrease the hepatitis C virus to undetectable levels, effectively providing a cure for the disease. Early successful treatment is also likely to lessen the social stigma that can be associated with hepatitis C infection later in life," said Carole Longson, director of the NICE health technology evaluation centre.
Peginterferon alfa with ribavirin is currently the only licensed treatment in the UK for children and young people with chronic hepatitis C.